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Abstract 
Background: Inflammatory breast cancer (IBC) is a rare, aggressive breast cancer diagnosed clinically by the pres‑
ence of diffuse erythema, peau d’orange, and edema that arise quickly in the affected breast. This study evaluated the 
validity of medical records in Gharbiah, Egypt in identifying clinical signs/symptoms of IBC. For 34 IBC cases enrolled 
in a case–control study at the Gharbiah Cancer Society and Tanta Cancer Center, Egypt (2009–2010), we compared 
signs/symptoms of IBC noted in medical records to those recorded on a standardized form at the time of IBC diagno‑
sis by clinicians participating in the case–control study. We calculated the sensitivity and specificity of medical records 
as compared to the case–control study for recording these signs/symptoms. We also performed McNemar’s tests.
Results: In the case–control study, 32 (94.1%) IBC cases presented with peau d’orange, 30 (88.2%) with erythema, 
and 31 (91.2%) with edema. The sensitivities of the medical records as compared to the case–control study were 0.8, 
0.5, and 0.2 for peau d’orange, erythema, and edema, respectively. Corresponding specificities were 1.0, 0.5, and 1.0. 
p values for McNemar’s test were <0.05 for all signs. Medical records had data on the extent and duration of signs for 
at most 27% of cases for which this information was recorded in the case–control study. Twenty‑three of the 34 cases 
(67.6%) had confirmed diagnosis of IBC in their medical records.
Conclusion: Medical records lacked information on signs/symptoms of IBC, especially erythema and edema, when 
compared to the case–control study. Deficient medical records could have implications for diagnosis and treatment 
of IBC and proper documentation of cases in cancer registries.
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Background
Inflammatory breast cancer (IBC) is a rare and aggressive 
type of locally advanced breast cancer (LABC) character-
ized by diffuse erythema and edema (or peau d’orange) of 
the breast [1, 2]. The IBC diagnosis is primarily clinical 
but also requires pathological confirmation of cancer. It 
can be confused with other types of neglected LABC but 
is differentiated by the rapid onset of symptoms.
The definition of IBC according to the seventh edition 
of the American Joint Committee on Cancer (AJCC) 
Cancer Staging Manual has three requirements: (A) the 
presence of diffuse erythema, edema, and peau d’orange 
over at least one-third of the breast, and (B) rapid onset 
of symptoms, and; (C) a pathologic diagnosis of breast 
cancer. There is frequently no underlying tumor mass. 
Previous AJCC definitions of IBC have included variable 
proportions of breast involvement—from no specified 
proportion requirement (AJCC 5th edition) [3] to the 
“majority” of the breast (AJCC 6th edition) [4] to one-
third of the breast (AJCC 7th edition) [5]. Some countries 
have used different definitions of IBC, such as “pousee 
evolutive,” which is used in Tunisia [6].
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There is an urgent need to better identify this condi-
tion in population-based cancer registries around the 
world. In the surveillance, epidemiology and end results 
(SEER) database in the United States, IBC is defined by 
a combination of histology, stage, and Extent of Disease 
(EOD) codes, which accommodate changes in the AJCC 
definition over time. These codes are not routinely used 
in other population-based cancer registries around the 
world, including those in North Africa. Therefore, IBC is 
not routinely identified in most population-based cancer 
registries. Accurate registration of IBC in population-
based registries requires both a set of codes to capture 
the clinical characteristics as well as complete and accu-
rate recording of clinical signs and symptoms of IBC in 
routine medical records (MRs) and accommodating for 
different definitions to facilitate comparisons from differ-
ent time periods and locations.
To our knowledge, there have been no previous stud-
ies in which the signs of IBC noted in medical records 
have been compared to signs/symptoms systematically 
recorded at the time of diagnosis by clinicians who have 
been specifically trained in the diagnosis of IBC (i.e., a 
gold standard). Therefore, this study aimed to evaluate 
the validity of medical records from the Nile Delta region 




Over the past 5  years, an epidemiologic case–control 
study was developed and conducted by several of the 
co-authors in Egypt, Tunisia, and Morocco to enroll IBC 
patients based on clinical evidence and investigate the 
epidemiology of the disease. The Tanta Cancer Center 
(TCC) and the Gharbiah Cancer Society (GCS) were the 
sources of patients for the Gharbiah study site in Egypt. 
Patients were recruited and enrolled if (A) they were 
female, Egyptian, and at least 18 years old; (B) had ery-
thema and/or edema/peau d’orange in at least one-third 
of the breast; (C) did not have extensive ulceration; (D) 
had pathologic confirmation of cancer; (E) had no pre-
vious treatment for the present breast cancer, and; (F) 
had no history of breast cancer. The patients enrolled in 
this study were confirmed as IBC using the signs/symp-
toms present during clinical examinations in addition to 
pathological confirmation of cancer. During the period 
of 2009–2010, 40 patients were recruited from TCC and 
GCS and each case was given a unique study ID number.
Data collection
As part of the case–control study, information on signs 
and symptoms associated with diagnosis of IBC was col-
lected at the time of diagnosis on standardized forms 
based on the clinical examination by physicians partici-
pating in the case–control study. Information collected 
included the presence, extent, and duration of erythema, 
peau d’orange, and increase in breast size. In addition, 
information was collected on the following signs/symp-
toms of breast cancer that might be helpful in distin-
guishing IBC from other types of locally advanced breast 
cancer that are characterized by neglect and delayed 
diagnosis: the presence, size, and duration of a palpable 
mass, ulceration, and palpable axillary lymph nodes.
Abstraction forms were developed and used to identify 
possible IBC cases from medical records of the 2 study 
hospitals (TCC and GCS) during the same time period 
as the case–control study (2009–2010). The medical 
records collected included all patients who received neo-
adjuvant chemotherapy for breast cancer treatment at 
the same institutions. The same variables collected in the 
case–control study were included in the medical record 
abstraction.
Data analysis
Data analysis focused on: (A) identifying the IBC cases 
included in the case–control study who had medi-
cal records available; (B) identifying the concordance 
between the signs/symptoms collected for the case–
control study and the signs/symptoms recorded on the 
routine medical records; (C) calculating sensitivity and 
specificity for signs recorded in the medical records com-
pared to those recorded for the case–control study, and; 
(D) performing McNemar’s tests for each symptom to 
determine if there was a significant difference between 
the two data sources, taking into account the paired 
nature of the data. A p value less than 0.05 suggested 
significant discordance. In this study, peau d’orange and 
edema were combined and analyzed together as peau 
d’orange. Similarly, erythema and inflammation were 
combined and analyzed as erythema. All statistical analy-
sis was performed using SAS 9.2 (Cary, NC).
Medical records were available for 34 (85%) of the 40 
cases that were recruited in the case–control study. The 
6 remaining cases did not have medical records from 
GCS or TCC due to receiving treatment elsewhere. There 
were a number of additional variables abstracted from 
the medical records that were excluded from analysis 
in the present study, including the name of the examin-
ing physician for each patient, which is referenced in the 
discussion. The study was approved by the University of 
Nebraska Medical Center IRB Committee (Protocol 060-
13-EX) and the Gharbiah Cancer Society IRB Commit-
tee in Egypt. No patients were approached for this study 
and the secondary analysis of data of the medical records 
did not include any data of children. The consent was 
waived by the IRB Committees listed above in Egypt and 
Page 3 of 5Le et al. BMC Res Notes  (2017) 10:126 
Nebraska because of the secondary analysis of the aggre-
gate data of the study.
Results
Twenty-three of the 34 cases (67.6%) had confirmed IBC 
diagnosis in their medical records. According to case–
control study, 30 (88.2%) of the 34 patients recruited 
presented with peau d’orange, 30 (88.2%) presented with 
erythema, and 31 (91.2%) with an increase in breast size. 
In the medical records, 24 (70.6%) were recorded as hav-
ing peau d’orange, 18 (52.9%) as having erythema, and 7 
(20.6%) as having an increase in breast size (Table 1). Fur-
ther, case–control data on the size/extent and duration of 
peau d’orange was available for 29 (85.3%) and 24 (70.6%) 
of the 34 cases, respectively, whereas the same informa-
tion was available for only 8 (23.5%) and 9 (26.5%) of the 
34 cases, respectively, in the medical records. For ery-
thema, information on extent and duration was available 
for 30 (88.2%) and 23 (67.6%) cases, respectively. In the 
medical records, the same information was recorded for 
7 (20.6%) and 16 (47.1%) cases. Data regarding the extent 
of increase in breast size were available for 31 (91.2%) 
cases; 24 (70.6%) cases had information on duration 
of increase in breast size. Only 1 case from the medi-
cal records had information on the extent of increase in 
breast size, and 7 (20.6%) cases had information on dura-
tion of the symptom.
As shown in Table  2, peau d’orange had the highest 
sensitivity (80%) of the 3 signs and edema the lowest 
(0.22). Peau d’orange and edema had specificities of 100%, 
but results were based on very small sample sizes. Peau 
d’orange, erythema, and increase in breast size all had 
significant p-values (0.014, 0.0027, p  <  0.0001, respec-
tively) for the McNemar’s test. Only 5 cases had complete 
information in the medical records on presence, extent, 
and duration of erythema, peau d’orange, and edema/
increase in breast size.
Table 3 lists other signs that were also recorded in the 
case–control study. Presence of a palpable mass was 
recorded for 27 cases (79.4%) by clinicians participating 
in the case–control study, slight ulcerations for 5 cases 
(14.7%), and palpable axillary lymph nodes for 28 (82.4%) 
cases. Sensitivities for all three signs were around 0.60 
and specificities especially high for ulceration (0.97) and 
palpable lymph nodes (0.83). McNemar’s test for pres-
ence of a palpable mass and ulceration were not statisti-
cally significant (0.07 and 0.56, respectively).
Discussion
Our results suggest that there are serious limitations in 
the recording of signs and symptoms needed for the diag-
nosis of inflammatory breast cancer according to AJCC 
[5, 7] criteria in the medical records of the Tanta Can-
cer Institute and the Gharbiah Cancer Society in Tanta, 
Egypt. This was particularly true for erythema and for 
the extent and duration of all three signs (erythema, peau 
d’orange, and increase in breast size).
There may be a variety of reasons why examining phy-
sicians would fail to report all IBC signs and symptoms 
in patient medical records. IBC is a rare type of breast 
cancer and is not well understood by physicians in many 
places. For example, some physicians lack education 
regarding IBC diagnoses, as is the case among primary 
care physicians in Egypt and Tunisia [8]. This could be 
due to a paucity of emphasis on oncology during medical 
school, the fragmentation of cancer-focused education 
at both the undergraduate and graduate level, and the 
absence of continuing medical education post-graduation 
[9, 10].
Previous studies have found that physicians often fail 
to obtain or access continuing medical education (CME) 
modules, especially in developing countries, which 
thereby affects their knowledge regarding new cancer 
epidemiology and accurate cancer diagnosis and manage-
ment [8, 11–13]. CME is necessary to keep health pro-
fessionals up to date as the IBC definition evolves. There 
also needs to be increased emphasis on the standardiza-
tion of these cancer-focused education programs across 
institutions.
Strengths of this study included the use of a separate, 
ongoing case–control study as a gold standard. The 
case–control study was conducted by IBC-trained phy-
sicians who recruited patients based on a clinical exam 
Table 1 Comparison of  information available on the pres-
ence, extent, and duration of peau d’orange and erythema 
in the case–control study and in medical records (N = 34)
This table excludes the 6 cases that lacked medical record data
a Symptoms are not mutually exclusive
b Peau d’orange and/or Edema




  Presence 30 (88.2%) 24 (70.6%)
  Extent 29 (85.3%) 8 (23.5%)
  Duration 24 (70.6%) 9 (26.5%)
 Erythemaa,c
  Presence 30 (88.2%) 18 (52.9%)
  Extent 30 (88.2%) 7 (20.6%)
  Duration 23 (67.6%) 16 (47.1%)
 Increase in breast sizea
  Presence 31 (91.2%) 7 (20.6%)
  Extent 31 (91.2%) 1 (2.9%)
  Duration 24 (70.6%) 7 (20.6%)
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and recorded thorough information on the signs and 
symptoms present using standardized forms, allowing for 
comparison with medical record data. Limitations of this 
study include the relatively small number of IBC cases 
and variability in diagnoses due to the number of physi-
cians examining patients (N = 19, data not shown).
Conclusions
This study revealed deficits in the information recorded 
on medical records needed to identify IBC cases. Defi-
cient medical record information could negatively impact 
the diagnosis and treatment for IBC patients. Further-
more, deficient medical record information could affect 
the perceived prevalence of IBC and limit the ability 
to record IBC cases in cancer registries, which would 
thereby hinder the study of its management and preven-
tion epidemiology. Our findings support the need for a 
universal definition of IBC to help improve the reliabil-
ity of medical records for registry-based research or ways 
to accommodate for multiple definitions to facilitate IBC 
research in developing countries. Future studies should 
compare other Egyptian institutions as well as neighbor-
ing developing countries to determine the most appro-
priate method of maintaining medical records for reliably 
identifying IBC cases. Additionally, improvements in 
professional education regarding the symptoms and clin-
ical characteristics of IBC would allow future profession-
als to correctly diagnose true IBC cases as such and stay 
up to date upon diagnostic criteria and state of the art 
research surrounding IBC. International registries should 
also explore a standardized procedure for identifying and 
registering IBC cases.
Table 2 Comparison of  symptoms required for  IBC, as  recorded in  the case–control study (N =  34) versus  in medical 
records for patients recruited in the NAS
This table excludes the 6 cases from the case–control study that had no medical records
p-values are derived from McNemar’s tests
a  Edema and/or Peau d’Orange
b  Erythema and/or inflammation
Peau d’orangea Erythemab Increase in breast size
Case–control study Case–control study Case–control study
Yes No Yes No Yes No
Medical records
 Yes 24 0 16 2 7 0
 No 6 4 14 2 24 3
Sensitivity = 0.8 Sensitivity = 0.53 Sensitivity = 0.22
Specificity = 1.0 Specificity = 0.5 Specificity = 1.0
p = 0.014 p = 0.0027 p < 0.0001
Table 3 Comparison of  additional symptoms as  recorded in  the case–control study (N =  34) versus  in medical records 
for the same patients
This table excludes the 6 cases from the case–control study that had no medical records
p-values are derived from McNemar’s tests
Presence of palpable mass Ulceration Palpable axillary lymph nodes
Case–control study Case–control study Case–control study
Yes No Yes No Yes No
Medical records
 Yes 16 4 3 1 16 1
 No 11 3 2 28 12 5
Sensitivity = 0.59 Sensitivity = 0.6 Sensitivity = 0.57
Specificity = 0.43 Specificity = 0.97 Specificity = 0.83
p = 0.07 p = 0.56 p = 0.0023
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